clinical trial · NCT00550862
Study of INT 747 in Combination With URSO in Patients With Primay Biliary Cirrhosis (PBC)
Intercept Pharmaceuticals·phase2·terminated·n = 165
Liver Cirrhosis, BiliaryINT-747Ursodeoxycholic Acid (URSO)Placebo
brief summary
The primary hypothesis is that INT-747 will cause a reduction in alkaline phosphatase levels in Primary Biliary Cirrhosis patients, over a 12 week treatment period, as compared to placebo.
started
Oct 1, 2007
primary completion
Aug 1, 2009
completion
Dec 1, 2010
last updated
Feb 6, 2024
detailed description
None provided
official title
A Study of INT 747 (6α-ethyl Chenodeoxycholic Acid (6-ECDCA)) in Combination With Ursodeoxycholic Acid (URSO®, UDCA) in Patients With Primary Biliary Cirrhosis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol